American Head and Neck Society position statement on the use of PD ‐1 inhibitors for treatment of advanced cutaneous squamous cell carcinoma

Author:

Schmalbach Cecelia E.1ORCID,Ow Thomas J.2ORCID,Choi Karen Y.3,O'Leary Miriam4,Lin Alice5,Hughley Brian B.6,Emerick Kevin S.7ORCID,Moore Brian8,Lee Nancy Y.9,Zandberg Dan P.10ORCID,Wang Steven J.11

Affiliation:

1. Department of Otolaryngology – Head and Neck Surgery Temple University Philadelphia Pennsylvania USA

2. Department of Otorhinolaryngology – Head and Neck Surgery Montefiore Medical Center, Albert Einstein College of Medicine Bronx New York USA

3. Department of Otolaryngology – Head and Neck Surgery Penn State College of Medicine Hershey Pennsylvania USA

4. Department of Otolaryngology – Head and Neck Surgery Tufts University Boston Massachusetts USA

5. Department of Otolaryngology – Head and Neck Surgery Kaiser Permanente Los Angeles California USA

6. University of Florida Health Gainesville Florida USA

7. Department of Otolaryngology – Head and Neck Surgery Massachusetts Eye and Ear Infirmary Boston Massachusetts USA

8. Ochsner Medical Center New Orleans Louisiana USA

9. Memorial Sloan Kettering Cancer Center Head and Neck Radiation Oncology New York City New York USA

10. Division of Hematology/Oncology, Department of Medicine University of Pittsburgh Pittsburgh Pennsylvania USA

11. Department of Otolaryngology – Head and Neck Surgery University of Arizona Tucson Arizona USA

Publisher

Wiley

Subject

Otorhinolaryngology

Reference52 articles.

1. Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)

2. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

3. National Comprehensive Cancer Network.Squamous Cell Skin Cancer (Version 1.2022).https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf. Accessed 5/1/2022.

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3